Related references
Note: Only part of the references are listed.250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study (vol 8, pg 889, 2009)
P. O'Connor
LANCET NEUROLOGY (2012)
250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study (vol 8, pg 889, 2009)
P. O'Connor et al.
LANCET NEUROLOGY (2011)
Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta. (vol 9, pg 381, 2010)
D. Wynn et al.
LANCET NEUROLOGY (2010)
A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis
Gavin Giovannoni et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
Ludwig Kappos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta
Daniel Wynn et al.
LANCET NEUROLOGY (2010)
Cortical Lesions and Atrophy Associated With Cognitive Impairment in Relapsing-Remitting Multiple Sclerosis
Massimiliano Calabrese et al.
ARCHIVES OF NEUROLOGY (2009)
Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial
G. Comi et al.
LANCET (2009)
Magnetic resonance evidence of cortical onset of multiple sclerosis
M. Calabrese et al.
MULTIPLE SCLEROSIS JOURNAL (2009)
Evidence for relative cortical sparing in benign multiple sclerosis: a longitudinal magnetic resonance imaging study
M. Calabrese et al.
MULTIPLE SCLEROSIS JOURNAL (2009)
Accumulation of cortical lesions in MS: relation with cognitive impairment
S. D. Roosendaal et al.
MULTIPLE SCLEROSIS (2009)
Brain atrophy as an outcome measure for multiple sclerosis clinical trials A no-brainer?
Richard A. Rudick et al.
NEUROLOGY (2009)
Cortical lesions in primary progressive multiple sclerosis A 2-year longitudinal MR study
M. Calabrese et al.
NEUROLOGY (2009)
250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study (vol 8, pg 889, 2009)
P. O'Connor et al.
LANCET NEUROLOGY (2009)
250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study
Paul O'Connor et al.
LANCET NEUROLOGY (2009)
Extensive cortical inflammation is associated with epilepsy in multiple sclerosis
Massimiliano Calabrese et al.
JOURNAL OF NEUROLOGY (2008)
Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial
Daniel D. Mikol et al.
LANCET NEUROLOGY (2008)
Detection of cortical inflammatory lesions by double inversion recovery magnetic resonance imaging in patients with multiple sclerosis
Massimiliano Calabrese et al.
ARCHIVES OF NEUROLOGY (2007)
Full results of the evidence of interferon dose-response-European north American comparative efficacy (EVIDENCE) study:: A multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon β-1a for relapsing multiple sclerosis
Steven R. Schwid et al.
CLINICAL THERAPEUTICS (2007)
Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis:: a 3-year follow-up analysis of the BENEFIT study
Ludwig Kappos et al.
LANCET (2007)
Gray matter involvement in multiple sclerosis
Istvan Pirko et al.
NEUROLOGY (2007)
Extensive hippocampal demyelination in multiple sclerosis
Jeroen J. G. Geurts et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2007)
Localization of grey matter atrophy in early RRMS - A longitudinal study
Bertrand Audoin et al.
JOURNAL OF NEUROLOGY (2006)
Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes
L. Kappos et al.
NEUROLOGY (2006)
Cortical demyelination in multiple sclerosis: A substrate for cognitive deficits?
Alexandra Kutzelnigg et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2006)
The measurement and clinical relevance of brain atrophy in multiple sclerosis
RA Bermel et al.
LANCET NEUROLOGY (2006)
Grey matter pathology in multiple sclerosis
M Vercellino et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2005)
Diagnostic criteria for multiple sclerosis: 2005 Revisions to the McDonald Criteria
CH Polman et al.
ANNALS OF NEUROLOGY (2005)
Cortical demyelination and diffuse white matter injury in multiple sclerosis
A Kutzelnigg et al.
BRAIN (2005)
Gray and white matter volume changes in early RRMS - A 2-year longitudinal study
M Tiberio et al.
NEUROLOGY (2005)
Relating neocortical pathology to disability progression in multiple sclerosis using MRI
JT Chen et al.
NEUROIMAGE (2004)
Subpial demyelination in the cerebral cortex of multiple sclerosis patients
L Bo et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2003)
The clinico-radiological paradox in multiple sclerosis revisited
F Barkhof
CURRENT OPINION IN NEUROLOGY (2002)
Disease modifying therapies in multiple sclerosis - Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines
DS Goodin et al.
NEUROLOGY (2002)
Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis
WI McDonald et al.
ANNALS OF NEUROLOGY (2001)
A longitudinal study of brain atrophy and cognitive disturbances in the early phase of relapsing-remitting multiple sclerosis
R Zivadinov et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2001)
Effect of early interferon treatment on conversion to definite multiple sclerosis:: a randomised study
G Comi et al.
LANCET (2001)
Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis.
LD Jacobs et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Share Paper
